ERBB2 and breast carcinoma: Recently, two radioimmunoconjugates targeting different epitopes of human epidermal growth factor receptor-2 (HER2) — 89Zr-DFO-trastuzumab and 89Zr-DFO-pertuzumab — have shown significant clinical potential in patients with HER2-positive breast cancer 5, 6.